Dr. Reddy's Laboratories Limited has informed the Exchange that Board of Directors at its meeting held on May 12, 2026, recommended Final Dividend of Rs. 8 per equity share.
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.1 pts less than Nifty 100 and 0.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr. Reddy's reported FY26 revenues of Rs. 335.9 billion, up 3.2% YoY, but profit after tax fell 24% to Rs. 42.9 billion. Q4 was severely impacted by a Rs. 4.53 billion Shelf Stock Adjustment for Lenalidomide, Rs. 1.29 billion impairment from discontinuing CAR-T programs, Rs. 914 million impairment from discontinued Eftilagimod Alfa trial, Rs. 1.14 billion VAT provision, and Rs. 1.17 billion new Labour Codes provision. Gross margin compressed to 52.8% (vs 58.5% last year) and EBITDA margin fell to 22.8% (vs 28.3%). The board recommended a final dividend of Rs. 8 per share. The company also changed its statutory auditor from S.R. Batliboi to Deloitte Haskins & Sells, and appointed two new independent directors.
The stock may face pressure due to significant profit decline, margin compression, and multiple one-off charges in Q4. However, the dividend signals management confidence, and excluding one-offs, underlying business showed resilience with 3.2% revenue growth. The North America segment was the main drag, while Emerging Markets and India grew strongly.